Cancer Causes & Control

, Volume 29, Issue 3, pp 379–382 | Cite as

Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain

  • Marta SolansEmail author
  • Gemma Osca-Gelis
  • Raquel Comas
  • Josep Maria Roncero
  • David Gallardo
  • Rafael Marcos-Gragera
  • Marc Saez
Brief report


Determining chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) incidence is challenging for two reasons: cancer registries tend to underreport CLL cases and its diagnostic criteria changed markedly in 2008. No studies have reported incidence rates dealing with both difficulties, and thus CLL/SLL burden in Europe is currently uncertain. Herein, we present accurate CLL/SLL incidence in a Spanish region during 1998–2013, using the population-based Girona Cancer Registry (GCR). We detected an 18.2% under-reporting of CLL/SLL cases when combining records from the GCR and additional information sources (i.e., records of flow cytometry laboratories, hospital registries and hematologists’ databases). In addition, age-adjusted rates (using the 2013 European population) changed from 7.57 (95% CI 6.87; 8.30) in 1998–2008 to 6.35 (95% CI 5.51; 7.30) in 2009–2013. Overall, completeness of CLL/SLL data requires accurate diagnosis and reporting of cases. Revision of cancer registry operations to include CLL/SLL-specific surveillance is likely to ensure that the monitoring of this malignancy is entirely accurate.


Chronic lymphocytic leukemia Incidence Under-reporting 2008 Guidelines Cancer registry 



This work was supported by a grant from the Spanish Ministry of Health (FIS PI15/00966) and by CIBERESP (PhD contract to MS).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Sant M, Allemani C, Tereanu C et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116:3724–3734. CrossRefPubMedGoogle Scholar
  2. 2.
    Turesson I, Linet MS, Bjorkholm M et al (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int J cancer 121:2260–2266. CrossRefPubMedGoogle Scholar
  3. 3.
    Zent CS, Kyasa MJ, Evans R, Schichman SA (2001) Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 92:1325–1330CrossRefPubMedGoogle Scholar
  4. 4.
    Ruchlemer R, Zatlawi M, Fishler Y et al (2014) Cancer registries often underestimate the true incidence of CLL. Blood 124:5646Google Scholar
  5. 5.
    Call TG, Norman AD, Hanson CA et al (2014) Incidence of chronic lymphocytic leukemia and high count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer 1:2000–2005. CrossRefGoogle Scholar
  6. 6.
    Molica S, Giannarelli D, Mirabelli R et al (2014) Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines. Expert Rev Hematol 7:691–695. CrossRefPubMedGoogle Scholar
  7. 7.
    Healey R, Patel JL, de Koning L, Naugler C (2015) Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada. Leuk Res 39:429–434. CrossRefPubMedGoogle Scholar
  8. 8.
    Seftel MD, Demers AA, Banerji V et al (2009) High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 33:1463–1468. CrossRefPubMedGoogle Scholar
  9. 9.
    Brenner H, Gondos A, Pulte D (2008) Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 111:4916–4921. CrossRefPubMedGoogle Scholar
  10. 10.
    da Cunha-Bang C, Geisler CH, Enggaard L et al (2016) The Danish National Chronic Lymphocytic Leukemia Registry. Clin Epidemiol 8:561–565. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126:454–462. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shanafelt TD, Kay NE, Rabe KG et al (2009) Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 27:3959–3963. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. CrossRefGoogle Scholar
  14. 14.
    van den Broek EC, Kater AP, van de Schans SAM et al (2012) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer 48:889–895. CrossRefPubMedGoogle Scholar
  15. 15.
    Lenartova A, Johannesen TB, Tjønnfjord GE (2016) National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population-based data. Cancer Med 5:3588–3595. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)Carlos III Institute of HealthMadridSpain
  2. 2.Research Group on Statistics, Econometrics and Health (GRECS)University of GironaGironaSpain
  3. 3.Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of CataloniaCatalan Institute of OncologyGironaSpain
  4. 4.Haematological Service, University Hospital Dr. Josep Trueta, Catalan Institute of OncologyGironaSpain

Personalised recommendations